Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada
These results demonstrate that PNEU-C-21 can prevent a substantial number of cases and deaths while remaining highly cost-effective over a range of inputs and scenarios in Canada.
Authors
- Amanda J. Martino (ORCID: https://orcid.org/0000-0002-7680-9047)
- Donald E. Low (ORCID: https://orcid.org/0000-0002-3735-0958)
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
- Marie-Claude Meilleur
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck Canada Inc. (Canada) (CA)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1080/14760584.2025.2608811
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00